CLPT vs SYK
CLPT: ClearPoint Neuro develops real-time imaging-guided stereotactic systems for minimally invasive brain surgery and intracranial drug delivery. SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries.
Side-by-side fundamentals
| Metric | CLPT | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.03 | $309.24 | |
| Market cap as of 2026-07-23 | $453M | $119.6B | |
| P/E as of 2026-07-23 | n/a | 35.83 | |
| PEG as of 2026-07-23 | -0.45 | 3.29 | CLPT lower |
| Net margin as of 2026-07-23 | -71.6% | +13.2% | SYK higher |
| Gross margin as of 2026-07-23 | +62.3% | +64.2% | SYK higher |
| Operating margin as of 2026-07-23 | -65.2% | +19.7% | SYK higher |
| ROE as of 2026-07-23 | -141.0% | +15.1% | SYK higher |
| ROA as of 2026-07-23 | -37.0% | +7.1% | SYK higher |
| Debt / equity as of 2026-07-23 | 2.63 | 0.64 | SYK lower |
| Revenue growth (YoY) as of 2026-07-23 | +26.0% | +8.8% | CLPT higher |
| Revenue CAGR (3y) SEC XBRL | +21.6% | +10.8% | CLPT higher |
| Dividend yield as of 2026-07-23 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.23 | 0.78 | |
| 1-year return as of 2026-07-22 close | +40.3% | -21.7% | CLPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.